Overview: Luteinizing Hormone Testosterone Panel
Introduction: The Luteinizing Hormone Testosterone Panel is a diagnostic tool designed to assess reproductive hormones using serum samples. In India, male hypogonadism and infertility affect ~10-20 percent of couples seeking fertility care, with low testosterone + abnormal LH indicating primary (testicular failure) or secondary (pituitary/hypothalamic) causes. High morbidity from under-testing in rural/low-SES men with low libido, erectile dysfunction, infertility, or fatigue, limited endocrine labs, delayed testosterone replacement or clomiphene leading to reduced quality of life or missed paternity. Per endocrinology practices aligned with ICMR, Endocrine Society of India, and Indian Society for Assisted Reproduction guidelines, the test employs immunoassay for LH and total testosterone over 1-2 days with high accuracy, valuable for differentiating hypogonadism types and guiding therapy. This diagnostic falls under hormonal screening and targets men with symptoms or abnormal semen analysis, addressing accurate detection to initiate replacement or fertility treatment. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise androgen axis evaluation and improving male reproductive health. Its serum-based approach ensures reliable hormone measurement.
Other Names: LH Testo Pnl.
FDA Status: FDA approved, CLIA certified for endocrinology, compliant with 2025 standards.
Historical Milestone: LH/testosterone panel standard; in India, used in andrology clinics.
Purpose: The test assesses 2 parameters including LH to guide reproductive hormone evaluation, differentiate hypogonadism, inform therapy.
Test Parameters: 1. LH, 2. Total Testosterone.
Pretest Condition: Fasting 10-12 hours recommended (morning sample ideal); patients should report low libido or infertility.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on erectile function, infertility, puberty.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated hypogonadism including infertility, benefits of assessment, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or diurnal variation can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Low testosterone + high LH indicates primary failure; low/normal LH suggests secondary, necessitating specialist input.
Specialist Consultation: Endocrinologists or andrologists should be consulted for management.
Additional Supporting Tests: FSH, semen analysis for confirmation.
Test Limitations: Morning sample critical; comprehensive approach required.
References: Indian Journal of Endocrinology 2024, Andrology Studies India 2023.
